Draft monograph: Liraglutide — submissions

Quantitative claims are reproduced without the method that produced them

The draft on Liraglutide was read in full. The respondent notes at the outset that this class has an unusually deep randomised evidence base, and that a monograph on it is fairly judged against a higher standard than one on a compound with none.

Several figures in the draft are quoted from sources that determined them by different methods. A figure obtained by one determination and a figure obtained by another are not comparable, and the draft places them in the same sentence without distinguishing them.

The respondent, an analytical chemist, proposes that every quantitative claim carry the method that produced it at the point of use rather than in the reference.

The pharmacokinetic section does not connect half-life to the dosing schedule

The respondent has read the draft monograph on Liraglutide against a caseload in which incretin analogues are prescribed daily.

The draft reports a half-life and, separately, a dosing interval. The respondent, a clinical pharmacologist, states that the relationship between the two is what determines accumulation and time to steady state, and that the monograph leaves the reader to derive it.

The respondent proposes that time to steady state be stated explicitly, with the assumption from which it was derived.

Mechanistic claims for a peptide fragment are carried without evidence that the fragment acts as described

The draft on Liraglutide is a substantial document and the respondent has confined this submission to one matter.

The respondent states that the draft repeats a mechanistic account originating in supply documentation rather than in the primary literature, and that the account attributes activity to a fragment on the basis of the activity of the parent molecule.

The respondent proposes that any mechanistic claim be traceable to a primary source and removed where it is not.

Glycaemic trials and weight-management trials are drawn on interchangeably

The respondent submits on the draft monograph for Liraglutide. The observation arises from teaching the material rather than from prescribing it.

The compound has two trial programmes with different populations, different doses and different endpoints. The monograph draws on both without saying which programme a given estimate came from, so a reader takes a weight figure obtained at one dose in one population as though it applied at the other.

The respondent proposes that the programme be named against every effect estimate in the assessed-outcome table.

The respondent notes submission 003 above and does not repeat the ground it covers.

The monograph should reproduce the approved labelling rather than paraphrase it

The respondent read the draft on Liraglutide alongside the approved labelling for the class, and submits on one matter arising.

The submission is made on behalf of the marketing-authorisation holder. It states that the draft paraphrases the approved indication, the posology and the contraindications, and that any paraphrase risks diverging from the authorised text.

The sponsor asks that the authorised wording be reproduced verbatim in each case, and offers the current summary of product characteristics as the source.

Submission 002 raises an adjacent matter. The respondent regards the two as separable and addresses only this one.

Open-label extension data are presented alongside randomised data without distinction

This submission concerns the draft on Liraglutide. The respondent assesses incretin-class evidence for a national body and comments in a personal capacity.

Long-term figures in the clinical section come from open-label extensions in which every participant received the active compound and those who did not tolerate it had already withdrawn. They are printed in the same table as randomised comparisons and in the same typeface.

The respondent proposes that extension data be presented in a separate table, or at minimum in a separately labelled block, and that the surviving-population problem be stated once where it arises.

The analytical section is longer than the clinical assessment it accompanies

This submission addresses the draft monograph on Liraglutide. The respondent went through the document twice, once as a specialist and once as a reader arriving without the background.

The respondent states that the analytical section occupies more of the monograph than the assessment of clinical effect, and that the proportions imply the Institute considers the analytical question the more important one.

The respondent proposes that the analytical material be moved to the standards series and referenced rather than reproduced.

The population to which the headline estimate applies is not stated with the estimate

Having reviewed the draft on Liraglutide, the respondent makes a single submission, on the view that one point put clearly is more use to the secretariat than six put together.

The draft carries a headline effect estimate in the abstract without the eligibility criteria of the trials that produced it. The respondent states that the estimate applies to a trial population with specific age, comorbidity and baseline criteria, and that a reader will apply it to whoever is in front of them.

The respondent proposes a one-line population statement adjacent to every headline estimate.